Biopharmaceutical
Medical
Biotechnology

Arrowhead Pharmaceuticals

$18.42
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.35 (1.94%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell ARWR and other stocks, options, ETFs, and crypto commission-free!

About

Arrowhead Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them. Read More The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Employees
116
Headquarters
Pasadena, California
Founded
1989
Market Cap
1.67B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.97M
High Today
$18.53
Low Today
$18.16
Open Price
$18.23
Volume
497.42K
52 Week High
$22.39
52 Week Low
$6.26

Collections

Biopharmaceutical
Medical
Biotechnology
Pharmaceutical
Health
Therapy
Technology

News

Simply Wall StMar 21

Is Arrowhead Pharmaceuticals, Inc.’s (NASDAQ:ARWR) CEO Salary Justified?

Chris Anzalone became the CEO of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) in 2007. First, this article will compare CEO compensation with compensation at similar sized companies. After that, we will consider the growth in the business. Third, we’ll reflect on the total return to shareholders over three years, as a second measure of business performance. This method should give us information to assess how appropriately the company pays the CEO. View our latest analysis for Arrowhead Pharmaceuticals H...

372
Seeking AlphaMar 11

Arrowhead Pharmaceuticals begins dosing in phase 1 study of ARO-APOC3

Arrowhead Pharmaceuticals (NASDAQ:ARWR) has dosed the first subjects in a Phase 1 clinical study of ARO-APOC3, an RNAi-based investigational medicine targeting Apolipoprotein C-III (apoC-III) being developed for the treatment of hypertriglyceridemia.

757
The Motley FoolMar 11

Here's Why Arrowhead Pharmaceuticals Gained 38.2% in February

What happened Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) rose more than 38% last month, according to data from S&P Global Market Intelligence. The incredible rise was catalyzed by fiscal first-quarter 2019 operating results, highlighted by a licensing deal with Johnson & Johnson subsidiary Janssen. Of course, it will take many years before investors know whether the collaboration will live up to its potential. That might help to explain why shares of Arrowhead Pharmaceuticals have dropped 6% since ...

468

Earnings

-$0.19
$0.05
$0.30
$0.54
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected May 7, After Hours

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.